Becton, Dickinson and Company $BDX Shares Sold by Mitchell Mcleod Pugh & Williams Inc.

Mitchell Mcleod Pugh & Williams Inc. lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,187 shares of the medical instruments supplier’s stock after selling 184 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Becton, Dickinson and Company were worth $549,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock valued at $18,808,000 after acquiring an additional 27,581 shares during the last quarter. FORA Capital LLC acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at about $3,458,000. GAMMA Investing LLC increased its stake in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at about $224,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDX. Royal Bank Of Canada began coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Morgan Stanley boosted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Stock Up 0.9%

NYSE BDX opened at $188.31 on Wednesday. The stock has a market cap of $53.97 billion, a PE ratio of 33.87, a P/E/G ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business has a 50 day moving average price of $190.46 and a two-hundred day moving average price of $185.47. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.